TNFSF11 and periodontitis: In an experimental periodontitis mouse model, intraperitoneal administration of anti‐RANKL antibodies prevents alveolar bone loss, and the inhibitory effects are greater than bisphosphonates (Kuritani et al., 2018), suggesting that denosumab may be more useful for preventing alveolar bone loss in periodontitis.